Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;35(8):e15625.
doi: 10.1111/dth.15625. Epub 2022 Jun 27.

Clinical efficacy of mychophenolate mofetil in treating lichen planopilaris

Arghavan Azizpour  1   2 , Parvaneh Hatami  1 , Vahideh Lajevardi  1   2 , Mehran Mohammadi  1 , Zeinab Aryanian  1   3 , Nessa Aghazadeh Mohandesi  4
Affiliations

Clinical efficacy of mychophenolate mofetil in treating lichen planopilaris

Arghavan Azizpour et al. Dermatol Ther. 2022 Aug.

Abstract

Lichen planopilaris (LPP) is a chronic inflammatory disorder of hair without a proven effective and safe treatment. To objectively assess the clinical efficacy of mycophenolate mofetil (MMF) in patients suffering from LPP, a retrospective cohort study was conducted on 52 patients who treated with MMF (2 g/day) at least for 6 months. LPP activity index (LPPAI) before and after treatment was calculated and compared. Most of the patients were female and belonged to the age group of 50-60 years. All of the disease activity indices were significantly improved after 6 months of therapy (p < 0.001). The majority of patients had LPPAI 4-6 and 0-2, before and after treatment, respectively. After 6 months of treatment, half of patients showed a disease activity decrease (LPPAI reduced >25% compared to the baseline value). Systemic MMF is an effective and relatively safe treatment modality for patients with LPP and could lead to significant reduction in disease activity regarding both subjective and objective indices.

Keywords: LPPAI; MMF; cellcept; clinical efficacy; lichen planopilaris; mycophenolate mofetil.

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. Lajevardi V, Ghodsi SZ, Goodarzi A, Hejazi P, Azizpour A, Beygi S. Comparison of systemic mycophenolate mofetil with topical clobetasol in lichen planopilaris: a parallel-group, assessor- and analyst-blinded, randomized controlled trial. Am J Clin Dermatol. 2015;16(4):303-311. doi:10.1007/s40257-015-0122-z
    1. Goodman WT, Barrett TL. Lichen planopilaris. In: Bolognia JL, Jorrizo JL, Schafter JV, eds. Dermatology. Vol 1. Elsevier Saunders; 2012:190-191, 194, 196, 1106-1107, Vol. 2, 2178-2179.
    1. Spencer LA, Hawryluk EB, English JC III. Lichen planopilaris: retrospective study and stepwise therapeutic approach. Arch Dermatol. 2009;145(3):333-334.
    1. Racz E, Gho C, Moorman PW, Noordhoek Hegt V, Neumann HAM. Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review. J Eur Acad Dermatol Venereol. 2013;27(12):1461-1470.
    1. Sperling LC, Nguyen JV. Commentary: treatment of lichen planopilaris, some progress, but a long way to go. J Am Acad Dermatol. 2010;62(3):387-393.

Supplementary concepts

LinkOut - more resources